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Background
Systemic sclerosis (SSc) is characterized by widespread tis-
sue fibrosis including the myocardium. Diffuse myocardial
fibrosis can be detected non-invasively by extracellular
volume (ECV) imaging based on pre- and postcontrast T1
measurements using cardiovascular magnetic resonance
(CMR). We hypothesized that multiparametric CMR,
including T1 mapping, can detect subclinical myocardial
involvement and provide a comprehensive cardiac assess-
ment in patients with SSc.
Methods
19 SSc patients (18 female, mean age 55 ± 10 years) and
20 controls (19 female, mean age 56 ± 8 years) without
overt cardiovascular disease underwent CMR at 1.5T.
CMR assessments included late gadolinium enhancement
(LGE) [IV gadoterate meglumine at 0.15 mmol/kg],
T1 mapping pre- and postcontrast, cine, tagging, and
T2-weighted imaging.
Results
Focal fibrosis on LGE was found in 10 SSc patients
(53%) but none of controls. Evidence of diffuse myocar-
dial fibrosis in SSc patients was supported by signifi-
cantly higher precontrast T1 values (1007 ± 29 vs. 958 ±
20 ms, p < 0.001) and expansion of ECV (35.4 ± 4.8 vs.
27.6 ± 2.5 %, p < 0.001). Regardless of any regional
fibrosis, indices of diffuse myocardial fibrosis were
significantly elevated in SSc and correlated with disease
activity and severity. Although biventricular size and
global function were preserved, peak systolic circumfer-
ential strain (-16.8 ± 1.6 vs. -18.6 ± 1.0, p < 0.001) and
peak diastolic strain rate (83 ± 26 vs. 114 ± 16 s-1, p <
0.001) were impaired in SSc. Impaired myocardial systo-
lic strain and diastolic strain rate inversely correlated
with diffuse myocardial fibrosis indices. There was no
evidence of myocardial edema in SSc.
Conclusions
Cardiac involvement is common in SSc even in the
absence of cardiac symptoms, and includes both focal
and ubiquitous diffuse myocardial fibrosis; this is asso-
ciated with impaired systolic and diastolic strain para-
meters, as well as disease activity and severity. CMR
may be useful in future in the study of treatments
aimed at preventing or reducing diffuse myocardial
fibrosis in SSc.
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Female sex, n (%) 19 (95) 18 (95) 0.74
Age, years 56 ± 8 55 ± 10 0.64
Hypertension, n (%) 2 (10) 4 (21) 0.41
Diabetes, n (%) 0 0 -
Hyperlipidaemia, n (%) 4 (20) 3 (16) 0.73
BMI, kg/m2 25 ± 4 27 ± 7 0.23
SSc VDAI N/A 4 ± 2 -
ESR, mm/hr (median, IQR) N/A 11 (3-18) -
CRP, mg/L (median, IQR) 3 (1-4) 5 (2-8) 0.01
Hemoglobin (g/L) 13 ± 1 12 ± 1 0.05
mRSS N/A 20 ± 6 -
LVEDV indexed, ml/m2 77 ± 16 69 ± 11 0.08
LVESV indexed, ml/m2 21 ± 5 18 ± 5 0.06
LVEF, % 73 ± 5 74 ± 6 0.52
LV Mass indexed, g/m2 52 ± 11 51 ± 8 0.74
LA size, mm 28 ± 5 37 ± 6 < 0.001
RVEDV indexed, ml/m2 85 ± 19 77 ± 12 0.32
RVESV indexed, ml/m2 28 ± 7 25 ± 7 0.06
RVEF, % 67 ± 4 67 ± 6 0.14
Mid SA circumferential strain -18.6 ± 1.0 -16.8 ± 1.6 < 0.001
Peak diastolic circumferential strain rate (s-1) 114 ± 16 83 ± 26 < 0.001
Presence of LGE (%) 0 10 (53) -
Volume fraction of LGE > 2SD (%) 0 3.8 ± 0.4 -
STIR T2 Ratio 1.6 ± 0.5 1.7 ± 0.4 0.66
BMI, body mass index; CRP, C-reactive protein; DMARD, disease modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; IQR, interquartile range; LA,
left atrium; LGE, late gadolinium enhancement; LV, left ventricle/ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction;
LVESV, left ventricular end-systolic volume; mRSS, modified Rodnan skin score; RVEDV; right ventricular end-diastolic volume; RVEF, right ventricular ejection
fraction; RVESD, right ventricular end-systolic volume; SA, short axis; SSc, systemic sclerosis; STIR, short Tau inversion recovery; VDAI, Valentini disease activity
index of the European Scleroderma Study Group
Figure 1 Baseline characteristics and CMR findings.
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